Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2024, with sales up 16.3% year on year to $1.18 billion. Its non-GAAP profit of $1.43 per share was 8% below analysts’ consensus estimates.